SCHEMBL7605565

SCHEMBL7605565

O=S(=O)(CCO)CCNc1nc(/C=C/c2cccnc2)nc2ccccc12

nearest known ligand 0.49

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
FLT3 P36888 14/20 0.49
ALDH1A1 P00352 2/20 0.48
LMNA P02545 1/20 0.48
HPGD P15428 1/20 0.48
PDE5A O76074 2/20 0.47
KDM4E B2RXH2 1/20 0.43
RAD1 O60671 1/20 0.43
MAPT P10636 1/20 0.43
CFTR P13569 1/20 0.43
APEX1 P27695 1/20 0.43
CASP6 P55212 1/20 0.43
KMT2A Q03164 1/20 0.43
RAD51 Q06609 1/20 0.43
HKDC1 Q2TB90 1/20 0.43
GOPC Q9HD26 1/20 0.43
TDP1 Q9NUW8 1/20 0.43
L3MBTL1 Q9Y468 1/20 0.43
GBA1 P04062 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7605570 1.00 FLT3 (0.49) FLT3ALDH1A1LMNAHPGDPDE5A
SCHEMBL7610192 0.82 GBA1 (0.50) FLT3ALDH1A1LMNAHPGDPDE5A
SCHEMBL7610184 0.82 GBA1 (0.50) FLT3ALDH1A1LMNAHPGDPDE5A
SCHEMBL7610843 0.82 ALDH1A1 (0.50) FLT3ALDH1A1LMNAHPGDPDE5A
SCHEMBL7610846 0.82 ALDH1A1 (0.50) FLT3ALDH1A1LMNAHPGDPDE5A
SCHEMBL7609640 0.81 ALDH1A1 (0.49) FLT3ALDH1A1LMNAHPGDPDE5A
SCHEMBL7609635 0.81 ALDH1A1 (0.49) FLT3ALDH1A1LMNAHPGDPDE5A
SCHEMBL7610465 0.79 GBA1 (0.53) ALDH1A1LMNAHPGDPDE5AKDM4E
SCHEMBL4698518 0.77 PDE5A (0.79) ALDH1A1LMNAPDE5AKDM4EMAPT
SCHEMBL5595373 0.77 PDE5A (0.79) ALDH1A1LMNAPDE5AKDM4EMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20020025968-A1 Method for inhibiting neoplastic cells and related conditions by exposure to 4-aminoquinazoline derivatives OSI PHARMACEUTICALS, INC. 2002-02-28 US disclosed
US-5439895-A Cardiovascular disorders; inhibitor of thromboxane A2 synthetase and cyclic guanosine 3',5'-monophosphate ONO PHARMACEUTICAL CO., LTD. (JP) 1995-08-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020025968-A1 Method for inhibiting neoplastic cells and related conditions by exposure to 4-aminoquinazoline derivatives VHL, MCL1, NFATC1 FLT3 3337/4885ALDH1A1 1566/4885LMNA 902/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.